CT-109-SN-38

N/A

Report date: 2025/01/26 18:14:48

Base Information

Drug NameCT-109-SN-38
Drug Alias NameCT-109 ADCanti-CEACAM-5/6 antibody drug conjugate (Stromatis Pharma/Eastern Virginia Medicinal school/Leidos)CT-109-SN-38
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 6 modulatorsCarcinoembryonic antigen related cell adhesion molecule 5 modulators
TargetsCarcinoembryonic antigen related cell adhesion molecule 6Carcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsColorectal NeoplasmsCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEastern Virginia Medical School
China Registration ClassN/A

Develop Information

Active CompaniesLeidos Biomedical Research IncStromatis Pharma IncEastern Virginia Medical School
Inactive CompaniesN/A
Active IndicationsColorectal NeoplasmsCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A